CRISPR Therapeutics raised €59M in a Series B round in Apr 2015. The company is based in Basel, Switzerland. Investors in the round: Abingworth LLP, Bayer Global Investments, Celgene and 5 others. Data as of 7 Aug 2026.
No source on record — unverified.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
